The Prescription Drug User Fee Act date, the FDA action date for this supplemental application, is scheduled for the fourth quarter of 2020.
The sNDA was based on results from the Phase III THALES trial, which showed aspirin plus Brilanta 90mg used twice daily for 30 days, resulted in a statistically significant and clinically meaningful reduction in the risk of the primary composite endpoint of stroke and death, compared to aspirin alone.
The results were in line with the known safety profile of Brilanta.
The data from the THALES trial will be published in a peer-reviewed journal and presented at an forthcoming medical congress.
Brilanta is not indicated in patients with minor acute ischemic stroke or high-risk transient ischemic attack.
Brilanta is approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome and in more than 70 countries for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack.
In May 2020, the Food and Drug Administration approved a label update for Brilanta in the US to include the reduction of the risk of a first heart attack or stroke in high-risk patients with coronary artery disease.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Hyperfine Inc and Athletic Heart collaborate to deliver portable brain imaging for former athletes
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy